Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

University of Toronto

$120,000.00

Interleaved TMS-fMRI to evaluate frontocingulate target engagement in treatment resistant depression: a blinded, sham-controlled neuroimaging and open-label efficacy trial

EF 2025-26

Résumé
Transcranial magnetic stimulation (TMS), a form of non-invasive brain stimulation approved in 2002 for treatment-resistant depression (TRD), offers great safety and tolerability. TMS protocols often involve 4-6 weeks of daily clinic visits for treatments, a much greater cost and burden relative to medications. Newer protocols such as intermittent theta-burst stimulation (iTBS) shortened treatment durations (from 20-40 to 3 min) with similar effectiveness. Recently, accelerated iTBS protocols (e.g. SAINT, FDA approved in 2022) which use personalized targets from functional magnetic resonance imaging (fMRI) connectivity-guided have reduced treatment duration to 1 week and improved efficacy by personalizing brain target selection. Still, ~30-50% of patients who receive TMS do not benefit, and most TMS protocols target the same anatomical brain region. As such, there is a great need to predict patients' clinical response prior to treatment, further optimize TMS protocols, and identify new targets. In this study, patients with TRD (N=88) first undergo a baseline fMRI scan to identify personalized brain targets for TMS. Next, they return for a TMS-fMRI visit, where they receive TMS at this personalized TMS brain target while undergoing another fMRI scan, to assess how their brain responds to various types of stimulation including standard iTBS and a similar "sham" (i.e. placebo-like) iTBS. Patients will not know (i.e. are blinded to) the order of active and sham stimulation. Soon after this visit, patients will undergo 5 days of personalized, accelerated iTBS with 8 treatments daily. Clinical outcomes are collected throughout. Patients' brain responses during the TMS-fMRI scan will be correlated with later improvement of clinical symptoms after accelerated iTBS treatment. In the future, this may guide psychiatrist decision-making in treatment selection for patients with treatment-resistant depression and aid design of new TMS protocols to improve clinical outcomes.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
559635
Name
Pople Christopher B
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Interleaved TMS-fMRI to evaluate frontocingulate target engagement in treatment resistant depression: a blinded, sham-controlled neuroimaging and open-label efficacy trial
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Biomarkers; Brain Stimulation; Depression; Functional Magnetic Resonance Imaging; Neuromodulation; Neuronavigation; Neuroplasticity; Prognosis; Tms-Fmri; Transcranial Magnetic Stimulation
Abstract
Transcranial magnetic stimulation (TMS), a form of non-invasive brain stimulation approved in 2002 for treatment-resistant depression (TRD), offers great safety and tolerability. TMS protocols often involve 4-6 weeks of daily clinic visits for treatments, a much greater cost and burden relative to medications. Newer protocols such as intermittent theta-burst stimulation (iTBS) shortened treatment durations (from 20-40 to 3 min) with similar effectiveness. Recently, accelerated iTBS protocols (e.g. SAINT, FDA approved in 2022) which use personalized targets from functional magnetic resonance imaging (fMRI) connectivity-guided have reduced treatment duration to 1 week and improved efficacy by personalizing brain target selection. Still, ~30-50% of patients who receive TMS do not benefit, and most TMS protocols target the same anatomical brain region. As such, there is a great need to predict patients' clinical response prior to treatment, further optimize TMS protocols, and identify new targets. In this study, patients with TRD (N=88) first undergo a baseline fMRI scan to identify personalized brain targets for TMS. Next, they return for a TMS-fMRI visit, where they receive TMS at this personalized TMS brain target while undergoing another fMRI scan, to assess how their brain responds to various types of stimulation including standard iTBS and a similar "sham" (i.e. placebo-like) iTBS. Patients will not know (i.e. are blinded to) the order of active and sham stimulation. Soon after this visit, patients will undergo 5 days of personalized, accelerated iTBS with 8 treatments daily. Clinical outcomes are collected throughout. Patients' brain responses during the TMS-fMRI scan will be correlated with later improvement of clinical symptoms after accelerated iTBS treatment. In the future, this may guide psychiatrist decision-making in treatment selection for patients with treatment-resistant depression and aid design of new TMS protocols to improve clinical outcomes.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Pople, Christopher B
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~